Amedisys Net Worth
Amedisys Net Worth Breakdown | AMED |
Amedisys Net Worth Analysis
Amedisys' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Amedisys' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Amedisys' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Amedisys' net worth analysis. One common approach is to calculate Amedisys' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Amedisys' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Amedisys' net worth. This approach calculates the present value of Amedisys' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Amedisys' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Amedisys' net worth. This involves comparing Amedisys' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Amedisys' net worth relative to its peers.
Enterprise Value |
|
To determine if Amedisys is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Amedisys' net worth research are outlined below:
| Over 96.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from prnewswire.com: Disposition of 23992 shares by Perkins Bruce D of Amedisys at 0.001 subject to Rule 16b-3 |
Amedisys Quarterly Good Will |
|
Amedisys uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Amedisys. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Amedisys' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Amedisys' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Amedisys is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Amedisys backward and forwards among themselves. Amedisys' institutional investor refers to the entity that pools money to purchase Amedisys' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of America Corp | 2025-03-31 | 606.2 K | Millennium Management Llc | 2025-03-31 | 605.6 K | Geode Capital Management, Llc | 2025-03-31 | 599.9 K | Balyasny Asset Management Llc | 2025-03-31 | 587.3 K | Cnh Partners, Llc | 2025-03-31 | 577.5 K | Water Island Capital Llc | 2025-03-31 | 558.4 K | Dimensional Fund Advisors, Inc. | 2025-03-31 | 509.3 K | Calamos Advisors Llc | 2025-03-31 | 487.4 K | Citadel Advisors Llc | 2025-03-31 | 465.5 K | Blackrock Inc | 2025-03-31 | 3.3 M | Vanguard Group Inc | 2025-03-31 | 3.2 M |
Follow Amedisys' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.32 B.Market Cap |
|
Project Amedisys' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.05 | 0.06 | |
| Return On Capital Employed | 0.06 | 0.06 | |
| Return On Assets | 0.02 | 0.01 | |
| Return On Equity | 0.04 | 0.04 |
When accessing Amedisys' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Amedisys' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Amedisys' profitability and make more informed investment decisions.
Please note, the presentation of Amedisys' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Amedisys' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Amedisys' management manipulating its earnings.
Evaluate Amedisys' management efficiency
Amedisys has return on total asset (ROA) of 0.0652 % which means that it generated a profit of $0.0652 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0667 %, meaning that it created $0.0667 on every $100 dollars invested by stockholders. Amedisys' management efficiency ratios could be used to measure how well Amedisys manages its routine affairs as well as how well it operates its assets and liabilities. At present, Amedisys' Return On Capital Employed is projected to increase slightly based on the last few years of reporting. The current year's Return On Equity is expected to grow to 0.04, whereas Return On Assets are forecasted to decline to 0.01. At present, Amedisys' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 92.4 M, whereas Intangible Assets are forecasted to decline to about 65.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 36.06 | 37.87 | |
| Tangible Book Value Per Share | (3.52) | (3.34) | |
| Enterprise Value Over EBITDA | 42.58 | 44.71 | |
| Price Book Value Ratio | 2.62 | 2.41 | |
| Enterprise Value Multiple | 42.58 | 44.71 | |
| Price Fair Value | 2.62 | 2.41 | |
| Enterprise Value | 8.8 B | 9.2 B |
Amedisys benefits from a proactive management team that anticipates market trends. Our analysis delves into how this proactive stance influences financial metrics and stock valuation.
Enterprise Value Revenue 1.4296 | Revenue | Quarterly Revenue Growth 0.052 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Amedisys insiders, such as employees or executives, is commonly permitted as long as it does not rely on Amedisys' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Amedisys insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Amedisys Corporate Filings
8K | 14th of August 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 12th of August 2025 Other Reports | ViewVerify | |
F4 | 8th of August 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 30th of July 2025 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Amedisys Earnings per Share Projection vs Actual
Amedisys Corporate Management
| John Nugent | Chief Officer | Profile | |
| Pete Hartley | CTO Systems | Profile | |
| Kendra Kimmons | VP Relations | Profile | |
| Jennifer Griffin | Chief Secretary | Profile | |
| Janet Britt | VP Collections | Profile | |
| Francis Mayer | Senior Development | Profile |
Already Invested in Amedisys?
The danger of trading Amedisys is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Amedisys is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Amedisys. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Amedisys is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Amedisys is a strong investment it is important to analyze Amedisys' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amedisys' future performance. For an informed investment choice regarding Amedisys Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amedisys. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.You can also try the AI Portfolio Prophet module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amedisys. If investors know Amedisys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amedisys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.14) | Earnings Share 2.57 | Revenue Per Share | Quarterly Revenue Growth 0.052 | Return On Assets |
The market value of Amedisys is measured differently than its book value, which is the value of Amedisys that is recorded on the company's balance sheet. Investors also form their own opinion of Amedisys' value that differs from its market value or its book value, called intrinsic value, which is Amedisys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amedisys' market value can be influenced by many factors that don't directly affect Amedisys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amedisys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amedisys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amedisys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.